08:00 , Feb 20, 2012 |  BC Week In Review  |  Clinical News

GeneChip System 3000Dx v regulatory update

Affymetrix said China's State Food and Drug Administration (SFDA) approved its GeneChip System 3000Dx v.2 for in vitro diagnostic use. The company said this is first microarray system approved in China for array-based diagnostics. The...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Company News

Clavis, Skyline Diagnostics deal

Skyline will investigate gene expression biomarkers to screen for patients with acute myelogenous leukemia (AML) that may benefit from Clavis' elacytarabine. The lipid Vector Technology (LVT) derivative of cytarabine (Ara-C) is in Phase III testing...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

AMLprofiler regulatory update

Skyline received CE mark approval in the EU for its AMLprofiler microarray in vitro diagnostic for acute myelogenous leukemia (AML). Skyline has already launched the test, which uses nucelophosmin ( NPM1 ; B23) technology from...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Skyline Diagnostics, Trovagene deal

Skyline received a license to use TrovaGene's nucleophosmin ( NPM1 ; B23) technology in Skyline's AMLprofiler microarray in vitro diagnostic test for acute myelogenous leukemia (AML). NPM1 mutation status is a biomarker for disease prognosis,...